Rock Springs Capital IMNM Position
Active6-Fund ConvergenceRock Springs Capital initiated a new position in Immunome Inc. (IMNM) in Q4 2025, holding $7.5M worth of shares across 347,666 shares.
IMNM is a convergence signal: 6 specialist biotech funds hold this stock, suggesting high institutional conviction.
Short interest stands at 16.3% of float with 17.4 days to cover, indicating significant bearish positioning against Rock Springs's long thesis.
1 insider purchase totaling $501K has been filed in the last 90 days, providing an additional conviction signal.
About Immunome Inc.
Immunome, Inc., a biopharmaceutical company, discovers and develops antibody therapeutics for oncology and infectious disease. The company's lead oncology program includes IMM-ONC-01, which targets IL-38 tumor-derived immune checkpoint capable of promoting evasion of the immune system. It also develops IMM-BCP-01, an antibody cocktail product candidate for the treatment of SARS-CoV-2 infections and COVID-19. The company was incorporated in 2006 and is headquartered in Exton, Pennsylvania.
Full company profile →Short Interest
16.3%
17.4 days to cover
Insider Buys (90d)
1
$501K total
Frequently Asked Questions
Does Rock Springs Capital own IMNM?
Yes. As of Q4 2025, Rock Springs Capital holds 347,666 shares of Immunome Inc. (IMNM) valued at $7.5M. This data comes from their SEC 13F filing.
How many hedge funds own IMNM?
6 specialist biotech hedge funds currently hold IMNM, including Redmile Group, EcoR1 Capital, Driehaus Capital and 2 more. When 3 or more specialist funds hold the same stock, BiotechEdge flags it as a convergence signal.
When did Rock Springs Capital first buy IMNM?
Rock Springs Capital's position in IMNM was first reported in Q4 2025. 13F filings are reported with a 45-day delay, so the actual purchase may have occurred earlier in the quarter.
Is Rock Springs Capital's IMNM position increasing or decreasing?
Rock Springs Capital initiated a new position in IMNM in the most recent quarter. This is their first reported holding.
Get the weekly biotech signal briefing
Fund moves, convergence shifts, insider buys, and catalyst alerts — delivered free every Monday.
IMNMCompany Page →
All fund holders, insider trades, catalysts, and cash runway
Rock Springs CapitalPortfolio →
Full 13F holdings, sector breakdown, and top movers
Drill into any signal
Fund Convergence
See which stocks multiple specialist funds are buying at once
Catalyst Calendar
Every PDUFA date, Phase 3 readout, and AdCom in one view
Insider Trading
When executives buy their own stock — the strongest bullish signal
Cash Runway
Which biotechs are running low on cash and face dilution risk
Short Squeeze
High short interest + fund buying + upcoming catalyst = squeeze setup
Signal Rankings
Every signal in one composite score — ranked by conviction
Biotech Movers
Stocks with the most signal activity right now across all signals
13F Changes
What top biotech funds bought and sold in the latest 13F filing
Want AI context on every signal? Start free trial →